Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Semaglutide vs Insulin Aspart in T2D (SUSTAIN 11)
NCT03689374Phase 3Completed
- Sponsor
- Novo Nordisk
- Start
- Oct 2018
- Primary completion
- Feb 2021
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 21
01
Overview
A Phase 3 trial of semaglutide in type 2 diabetes mellitus (T2DM), sponsored by Novo Nordisk. Started Oct 2018; status: completed.
02
Drugs
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT03689374.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03689374.